Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.72 |
| ▸ | RAD52 | P43351 | 1/20 | 0.72 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.72 |
| ▸ | TERT | O14746 | 15/20 | 0.72 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6367252 | 0.94 | MEN1 (0.81) | MEN1MAPTKMT2AALDH1A1POLB | |
| SCHEMBL8715813 | 0.85 | TERT (0.97) | MEN1MAPTKMT2AALDH1A1POLB | |
| SCHEMBL8710224 | 0.83 | TERT (1.00) | MEN1MAPTKMT2AALDH1A1POLB | |
| SCHEMBL8707585 | 0.82 | TERT (0.83) | MEN1MAPTKMT2AALDH1A1POLB | |
| SCHEMBL8706949 | 0.82 | TERT (0.78) | MEN1MAPTKMT2AALDH1A1POLB | |
| SCHEMBL20334206 | 0.81 | PIM1 (0.59) | MEN1MAPTKMT2AALDH1A1POLB | |
| SCHEMBL6366577 | 0.80 | TERT (0.64) | MEN1MAPTKMT2AALDH1A1POLB | |
| SCHEMBL1303246 | 0.80 | TERT (1.00) | MEN1MAPTKMT2AALDH1A1POLB | |
| SCHEMBL10046652 | 0.79 | NQO1 (0.59) | MEN1MAPTKMT2AALDH1A1POLB | |
| SCHEMBL11880339 | 0.76 | MAOA (0.67) | MEN1MAPTKMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691418-B2 | Composition for inhibiting or preventing the formation of a biofilm | OYSTERSHELL NV (BE) | 2010-04-06 | — | — | US | disclosed |
| US-20070258913-A1 | Composition for Inhibiting or Preventing the Formation of a Biofilm | OYSTERSHELL NV (BE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258913-A1 | Composition for Inhibiting or Preventing the Formation of a Biofilm | NQO2, NFKBIA, CROCC | MEN1 3614/4885MAPT 4695/4885KMT2A 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.